ImmunoPrecise Antibodies Ltd. (IPA.V)

9.27 -0.23 (-2.42%) As of 11:53AM EDT. Market open.

ImmunoPrecise Antibodies Ltd.

3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada
250 483 0308
http://www.immunoprecise.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. James S. Kuo M.B.A., M.D.	Independent Chairman	N/A	N/A	1965
Dr. Jennifer Lynne Bath Ph.D.	CEO, Pres & Director	1.06M	N/A	N/A
Ms. Lisa Helbling	Chief Financial Officer	438.46k	N/A	N/A
Dr. Yasmina Noubia Abdiche Ph.D.	Chief Scientific Officer	30.49k	N/A	N/A
Dr. Stefan Lang	Chief Bus. Officer	219.58k	N/A	N/A
Mr. David E. Orton	Chief Operating Officer	N/A	N/A	N/A
Ms. Lauren Smith	VP of Marketing and Sales	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Corporate Governance

ImmunoPrecise Antibodies Ltd.’s ISS Governance QualityScore as of April 30, 2021 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.